Journal Watch · Biomaterials · 2026

Computationally-guided multifunctional nanoplatform for enhanced oral delivery and targeted therapy of Helicobacter pylori using herbal bioactives.

Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.

Zhang C, Chen H, Zou Y et al.Biomaterials3 min readPharma relevance 40/100

DOI: 10.1016/j.biomaterials.2025.123517PMID: 40544638Study type: preclinical (animal / model) study

TL;DR

Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.

Key findings

  • In vivo evaluation using a H. pylori infected murine model revealed that T@PDA-FuSH effectively reduced H. pylori burden, alleviated inflammatory responses, and promoted the restoration of gastric mucosal integrity.
  • Importantly, this treatment modality preserved the homeostasis of the gastric microbiota, notably enhancing the abundance of beneficial probiotics such as Lactobacillus and Bifidobacterium.
  • Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.

What they did

Advanced computational methods-including density functional theory (DFT) calculations and molecular dynamics (MD) simulations-were employed to identify tanshinone I (Tan_I) as an optimal herbal candidate for encapsulation within a thiolated fucoidan-polydopamine (PDA-FuSH) nanocarrier. The resulting nanoplatform (T@PDA-FuSH) demonstrated exceptional stability, high drug-loading efficiency, and distinct gastric mucoadhesive properties, attributable to its strong binding affinity for gastric mucin MUC5AC. Furthermore, T@PDA-FuSH exhibited robust bactericidal activity against both standard H. pylori strains and drug-resistant clinical isolates.

Full abstract (original)

Background: Herbal bioactive ingredients offer considerable promise for the eradication of Helicobacter pylori (H. pylori) due to their inherent non-toxicity, cost-effectiveness, and diverse pharmacological activities. However, their clinical utility is frequently limited by poor oral bioavailability and insufficient accumulation at target sites. In this study, we fabricated a multifunctional nanoplatform for H. pylori-targeted therapy developed through a computationally guided design strategy.

What they did: Advanced computational methods-including density functional theory (DFT) calculations and molecular dynamics (MD) simulations-were employed to identify tanshinone I (Tan_I) as an optimal herbal candidate for encapsulation within a thiolated fucoidan-polydopamine (PDA-FuSH) nanocarrier. The resulting nanoplatform (T@PDA-FuSH) demonstrated exceptional stability, high drug-loading efficiency, and distinct gastric mucoadhesive properties, attributable to its strong binding affinity for gastric mucin MUC5AC. Furthermore, T@PDA-FuSH exhibited robust bactericidal activity against both standard H. pylori strains and drug-resistant clinical isolates.

Results & conclusions: In vivo evaluation using a H. pylori infected murine model revealed that T@PDA-FuSH effectively reduced H. pylori burden, alleviated inflammatory responses, and promoted the restoration of gastric mucosal integrity. Importantly, this treatment modality preserved the homeostasis of the gastric microbiota, notably enhancing the abundance of beneficial probiotics such as Lactobacillus and Bifidobacterium. Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.

Abstract © the authors / Biomaterials (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.biomaterials.2025.123517 · PubMed 40544638.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking Biomaterials for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Biomaterials study find?

Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.

What type of study is this?

It is a preclinical (animal / model) study, published in Biomaterials in 2026. Advanced computational methods-including density functional theory (DFT) calculations and molecular dynamics (MD) simulations-were employed to identify tanshinone I (Tan_I) as an optimal herbal candidate for encapsulation within a thiolated fucoidan-polydopamine (PDA-FuSH) nanocarrier.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.biomaterials.2025.123517. PubMed ID: 40544638. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang C, Chen H, Zou Y et al.. Computationally-guided multifunctional nanoplatform for enhanced oral delivery and targeted therapy of Helicobacter pylori using herbal bioactives.. Biomaterials (2026). DOI: 10.1016/j.biomaterials.2025.123517.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/computationally-guided-multifunctional-nanoplatform-for-enhanced-oral-de-123517/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides